Synapse - Anas Younes

Results (320)

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial

Journal Article

Karuturi, M.; Younes, A.; Fayad, L.; Kwak, L.; Pro, B.; Shah, J.; Oki, Y.; Simien, R.; Liboon, M. J.; Hutto, T.; more...
Leukemia and Lymphoma (2016)

Fulltext@MSK | Save

Lymphomas and microenvironment: Impact on lymphomagenesis

Journal Article

Carbone, A.; Younes, A.
Seminars in Cancer Biology (2015)

Fulltext@MSK | Save

Hodgkin's lymphoma

Book Section

Younes, A.; Carbone, A.; Johnson, P.; Dabaja, B.; Ansell, S.; Kuruvilla, J.
In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed (2015)

Fulltext@MSK | Save

The number of CD163-positive cells in the microenvironment and peripheral blood lymphocyte-to-monocyte-ratio (LMR) is associated with poor outcome in patients with diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Matsuki, E.; Bohn, O. L.; Pichardo, J.; Zelenetz, A.; Younes, A.; Teruya-Feldstein, J.
Cancer Research (2015)

Fulltext@MSK | Save

Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma

Meeting Abstract

Vogl, D. T.; Younes, A.; Stewart, K.; Orford, K. W.; Bennett, M.; Siegel, D.; Berdeja, J. G.
Blood (2015)

Fulltext@MSK | Save

Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma

Meeting Abstract

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
Blood (2015)

Fulltext@MSK | Save

Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Chen, R.; Gopal, A. K.; Smith, S. E.; Ansell, S.; Rosenblatt, J. D.; Savage, K. J.; Connors, J. M.; Engert, A.; Larsen, E. K.; Huebner, D.; more...
Blood (2015)

Fulltext@MSK | Save

Distinctive genomic alterations in testicular diffuse large B cell lymphoma

Meeting Abstract

Batlevi, C.; Rapaport, F.; Wang, L.; Intlekofer, A. M.; Copeland, A. R.; Jungbluth, A. A.; Reiner, A.; Pichardo, J. D.; Gallagher, M.; Bouvier, N.; more...
Blood (2015)

Fulltext@MSK | Save

Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay

Meeting Abstract

Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
Blood (2015)

Fulltext@MSK | Save

An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL)

Meeting Abstract

Younes, A.; Salles, G.; Martinelli, G.; Bociek, R. G.; Barrigon, D. C.; Barca, E. G.; Turgut, M.; Gerecitano, J. F.; Herbst, F.; Williams, L.; more...
Blood (2015)

Fulltext@MSK | Save